肿瘤细胞治疗研究
英文原题：Gain-of-function enhancers optimize CAR-NK cell-based anti-cancer immunotherapy.
用于识别NK细胞适应性基因的两阶段筛选方法示意图。
用于鉴定NK细胞适应性基因的两阶段筛选方法示意图概述。(A) CRISPRa机制，显示dCas9-VP64介导的靶基因上调。(B) 在转导了CRISPR sgRNA文库的HER2-CAR-NK92细胞中进行全基因组CRISPRa筛选，随后将这些细胞转移到荷HT29肿瘤的小鼠体内，之后进行肿瘤收集和下一代测序(NGS)。(C) 在转导了HER2-CAR和ORF文库的原代外周血NK(PBNK)细胞中进行带条形码的ORF小型筛选，随后将这些细胞转移到荷HT29肿瘤的小鼠体内，之后进行肿瘤收集和NGS分析。
Schematic overview of the two-stage screening approach used to identify NK cell fitness genes. (A) CRISPRa mechanism, showing dCas9-VP64-mediated upregulation of target genes. (B) Whole-genome CRISPRa screening in HER2-CAR-NK92 cells transduced with a CRISPR sgRNA library and transferred into mice bearing HT29 tumours, followed by tumour collection and next-generation sequencing (NGS). (C) Barcoded ORF mini-screen in primary peripheral blood NK (PBNK) cells transduced with HER2-CAR and an ORF library, transferred into HT29 tumour-bearing mice, with subsequent tumour collection and NGS analysis.
MEMBER ACCOUNT
登录成功会直接打开下一页。
